Therapeutic Advances in the Treatment of CLL: Focus on Inhibitors of the BCR Signaling Pathways

This information was originally presented on March 15, 2014, at the NCCN 19th Annual Conference: Advancing the Standard of Cancer Care™ held in Hollywood, Florida.

Target Audience

This activity is designed to meet the educational needs of physicians, nurses, pharmacists, and other clinical professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Integrate into professional practice the key updates of the NCCN Guidelines related to chronic lymphocytic leukemia
  • Describe the mechanism of action, as well as the main efficacy and safety results from clinical studies with the PI3K-delta inhibitor idelalisib and BTK inhibitor ibrutinib
Additional information
Supporters: 

Supported by educational grants from:

  • Bristol-Myers Squibb
  • Novartis Oncology
  • Spectrum Pharmaceuticals, Inc.
  • Takeda Oncology

Supported by a grant from:

  • Onyx Pharmaceuticals
Course summary
Available credit: 
  • 0.75 Participation
  • 0.81 Nurse
  • 0.75 Pharmacist
  • 0.75 Physician
Course opens: 
04/29/2014
Course expires: 
04/29/2015
Cost:
$0.00
Part of: 
Recorded Presentations from the NCCN 19th Annual Conference: Hematologic Malignancies

John C. Byrd, MD
The Ohio State University Comprehensive Cancer Center –
James Cancer Hospital and Solove Research Institute

Available Credit

  • 0.75 Participation
  • 0.81 Nurse
  • 0.75 Pharmacist
  • 0.75 Physician

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
  • Adobe Reader for certificate viewing/printing